Drug intelligence / Profile preview

GS-0272

Development stage: Preclinical
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

GS-0272 is an investigational small molecule drug developed by Gilead Sciences. It acts as a blocker of the B and T lymphocyte attenuator (BTLA), a co-inhibitory receptor involved in immune regulation. By inhibiting BTLA, GS-0272 is designed to modulate immune responses, potentially reducing inflammation associated with autoimmune diseases. The drug is currently being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics in adult participants with rheumatoid arthritis (RA) in Phase 1 clinical trials. It was also previously under development for systemic lupus erythematosus (SLE)[1][4][7].

Targets

BTLA

Beyond the preview

Go deeper on GS-0272.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-0272.

Explore the full profile